πŸ‡ΊπŸ‡Έ FDA
Patent

US 11859000

Anti-CCR8 antibodies and uses thereof

granted A61KA61K39/39541A61K47/6849

Quick answer

US patent 11859000 (Anti-CCR8 antibodies and uses thereof) held by VACCINEX, INC. expires Mon Dec 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
VACCINEX, INC.
Grant date
Tue Jan 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K39/39541, A61K47/6849, A61P, A61P35/00